Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

CEO

Dr. John A. Scarlett M.D.

Market Cap

1.80 Billion USD

Sector

Healthcare

Website

https://www.geron.com

Last Update

2/22/2024, 12:00:00 PM

Description

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.

Read More

Overview

Value

0

Growth

20

Health

44

Management

0

Analyst Opinion

51

Total

36

All Scores Out Of 100

Best Features

  • Earnings growth has improved recently
  • Has a low level of debt
  • Low preportion of income is paid as dividend

Risk Factors

  • Overvalued on cashflow basis
  • Income is not covering expenditure and investment
  • Earnings are negative
  • Altman-Z score suggests a risk of bankruptcy
  • Disliked by Twitter users
  • Poor earnings and cashflow growth
  • Dividend could be at risk

Market Peers

GERN

Key Figures

PE Ratio (TTM)

N/A

Margin Of Safety (DCF)

N/A

Revenue Growth (5 Year Average)

N/A

Ratings Consensus

Neutral

Share Buybacks

N/A

Dividend Yeild (TTM)

0.00%

Valuation

Value Score

0

  • Estimated intrinsic-value of N/A is lower than current price ( 3.30 USD)
  • Free-cashflow-yeild of -16.36% is worse than the market average (4.7%)
  • Margin-of-safety of N/A is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: N/A

Current Price: 1.9 USD

Negative Cashflows: Cashflow can become negative due to operating losses, investing activities or financing activites. Negative cashflow makes it dificult to use a discounted free cashflow model to assess intrinsic value.

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

N/Ax

Free Cashflow Yeild

-16.36%

PE/Earnings Growth

N/A

Price/Book

4.14x

Growth

Growth Score

20

  • Earnings growth has improved this year
  • 5 Year Average Revenue growth of N/A is lower than the market average (10.97%)
  • Revenue growth has slowed this year
  • 5 Year Average Earnings growth of N/A is lower than the market average (14.48%)
  • 5 Year Average Free Cashflow growth of N/A is lower than the market average (12.35%)
  • Free Cashflow growth has slowed this year

Revenue Growth

N/A

Earnings Growth

N/A

Cashflow Growth

N/A

Health

Health Score

44

  • Has a low level of debt
  • Assets cover liabilities
  • Normal operation does not require debt to be sustainable
  • Cashflow is negative
  • Altman-Z score suggests a risk of bankruptcy
  • Debt repayments significantly impact cashflow

Altman Z Score

0.00

Piostroski Score

2.00

Debt/Equity

0.44x

Current Assets/Liabilities

4.11x

Free Cashflow/Total Debt

0.00x

Debt/Capital

0.29x

Dividend

Secure Dividend Score

0

  • Long term dividend payout ratio of 0.00% is considered good
  • Payout ratio (TTM) of 0.00% is lower than the average (40%)
  • Dividends have shown growth over the last 5 years
  • Spending a lower percentage of their income on dividends than last 5 years
  • Dividend yeild of 0.00% is less than the market average (1.85%)
  • Very unsafe

Dividend Yeild

0.00%

Dividend Growth

N/A

Payout Ratio (Earnings)

0.00%

Payout Ratio (Cashflow)

0.00%

Management

Management Score

0

  • Return-on-capital-employed of -40.80% is lower than the market average (10%)
  • Return-on-equity of -151.18% is lower than the market average (15%)

Average Buybacks/Dilution

N/A

Recent Buybacks/Dilution

66.67%

5 Year Price Volitility

13.36%

Return On Assets

-84.55%

Return On Capital Employed

-40.80%

Return On Equity

-151.18%

Return On Free Cashflow

N/A

Return On Investments

-107.67%

Social Sentiment

Social Sentiment Score

27

Twitter Sentiment

0.00

Stocktwits Sentiment

53.00

Analysts

Analyst Opinion

51

  • Ratings consensus is Neutral

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Geron Corporation

Currency

USD

Beta

0.862704

Vol Avg

6476390

Ceo

Dr. John A. Scarlett M.D.

Cik

0000886744

Cusip

374163103

Exchange

NASDAQ Global Select

Full Time Employees

107

Industry

Biotechnology

Sector

Healthcare

Ipo Date

1996-07-31

Address

919 East Hillsdale Boulevard

City

Foster City

State

CA

Country

US

Zip

94404

Phone

650 473 7700

Analysis Last Updated

2/22/2024, 12:00:00 PM

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies